Josh Cohen, Justin Klee
Armed with positive ALS data, Amylyx scores $30M in fresh funding to complete Alzheimer's PhII
Four years after announcing themselves to the biotech world with a new idea for drugging neurodegeneration, backing by the late Henri Termeer and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
